Skip to content
OpenCapital
Get started

MiMedx Group MDXG Investigation, restatement and related

Investigation, restatement and related at other companies

Alphatec Holdings logo
Alphatec HoldingsATEC
$525K-95.7%
CSL
Carlisle CompaniesCSL
$1M-61.5%
Medline, Inc. logo
Medline, Inc. MDLN
$1.42B+13.2%
CF Industries logo
CF IndustriesCF
$111M+192%
Commercial Metals logo
Commercial MetalsCMC
$90.57M—
APO
Apogee EnterprisesAPOG
$9.4M—

Other financials

Income statement

See full
Revenue$59.0M-33.1%
Gross profit$41.6M-41.9%
Operating income-$16.0M-295%
Net income-$10.9M-255%
EPS (diluted)-$0.07-240%

Balance sheet

See full
Cash & equivalents$159.8M+50.1%
Total debt$17.6M-5.7%
Total equity$242.9M+19.8%
Total assets$308.7M+14.1%

Cash flow

See full
Operating cash flow$1.9M-64.5%
CapEx$570.0K+51.2%
Free cash flow$1.3M-73.4%

Valuation

See full
Market cap$567.48M-33.9%
Enterprise value$425.3M-44.8%
P/E18.5×-2.9×
P/S1.5×-1.0×

Profitability

See full
Gross margin81%-0.9pp
Operating margin10.2%-5.1pp
Net margin7.9%-3.5pp
FCF margin17.8%-0.5pp

Returns & leverage

See full
Return on equity13.8%-8.6pp
Debt / equity0.1×0.0×
Current ratio5.4×+0.7×

Where this comes from

Reported directly by MiMedx Group in its filing.

Tagged under the XBRL concept mdxg:InvestigationRestatementAndRelatedExpenseBenefit.

The official record: MiMedx Group’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiMedx Group's investigation, restatement and related.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiMedx Group's investigation, restatement and related?
MiMedx Group (MDXG) reported investigation, restatement and related of $0 in Q4 2025.
How has MiMedx Group's investigation, restatement and related changed year-over-year?
MiMedx Group's investigation, restatement and related increased by 100.0% year-over-year, from -$2.17M to $0.
What is the long-term trend for MiMedx Group's investigation, restatement and related?
Over 3 years (2022 to 2025), MiMedx Group's investigation, restatement and related has grown at a -100.0% compound annual growth rate (CAGR), from $12.18M to $0.
What does investigation, restatement and related mean?
This metric represents non-recurring costs associated with internal investigations, financial restatements, and related legal or regulatory compliance activities. These expenses reflect the financial impact of governance, oversight, or accounting remediation efforts that fall outside of normal business operations. Investors monitor these costs to assess the magnitude of organizational risk and the potential for long-term operational disruption.